17 research outputs found
ΠΡΠ±ΠΎΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΡ Π²Π½ΡΡΡΠΈΠ³Π»Π°Π·Π½ΠΎΠ³ΠΎ Π΄Π°Π²Π»Π΅Π½ΠΈΡ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ Π³ΠΈΠΏΠΎΡΠ΅Π½Π·ΠΈΠ²Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π°Π½ΡΠΈΠ³Π»Π°ΡΠΊΠΎΠΌΠ½ΡΡ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉ
Purpose of this study β to compare the results of different tonometry methods before surgical treatment of glaucoma and in the early postoperative period.The study was conducted on a group of 50 patients (50 eyes) aged 55 to 80 years with uncompensated primary open-angle glaucoma, who were admitted to in-patient department for glaucoma surgery. Patients were examined using bidirectional applanation tonometry of the cornea performed on Ocular Response Analyzer, pneumotonometry on Canon TX-20P device, and with Icare tonometer. These studies were carried out on the day before the surgery, the next day, and 2 weeks after the operation.Significant differences in tonometry readings were revealed between all tested devices at high intraocular pressure (IOP) levels (before glaucoma surgery). Significant differences were also found in IOP values obtained with Icare tonometer in the central zone of the cornea and in the middle periphery in the nasal and temporal sectors. A significant difference between the indicators remained on the next day after surgery, except for the Icare readings. After two weeks, the tonometric parameters did not differ significantly from each other.Corneal compensated IOP (IOPcc) is the most important tonometric indicator in clinical practice because it takes into account the individual biomechanical characteristics of the patientβs cornea. When examining patients with glaucoma, the IOPcc indicator significantly differed in uncompensated IOP, which is important for determining the correct treatment tactics. When assessing the level of IOP after surgery this trend persisted, indicating a systematic underestimation of IOP level (overestimation of the effect of glaucoma surgery). The reliability of the study is confirmed by the results of measurements on unoperated fellow eyes (control).Π¦Π΅Π»Ρ β ΡΡΠ°Π²Π½ΠΈΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠ°Π·Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΡΠΎΠ½ΠΎΠΌΠ΅ΡΡΠΈΠΈ Π΄ΠΎ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π³Π»Π°ΡΠΊΠΎΠΌΡ ΠΈ Π² ΡΠ°Π½Π½Π΅ΠΌ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΈΠ· 50 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (50 Π³Π»Π°Π·) Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 55 Π΄ΠΎ 80 Π»Π΅Ρ Ρ Π½Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΡΠΊΡΡΡΠΎΡΠ³ΠΎΠ»ΡΠ½ΠΎΠΉ Π³Π»Π°ΡΠΊΠΎΠΌΠΎΠΉ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΠΎΡΡΡΠΏΠ°Π»ΠΈ Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°Ρ Π΄Π»Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Π°Π½ΡΠΈΠ³Π»Π°ΡΠΊΠΎΠΌΠ½ΠΎΠΉ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ. ΠΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π΄Π²ΡΠ½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠ°ΠΏΠ»Π°Π½Π°ΡΠΈΠΈ ΡΠΎΠ³ΠΎΠ²ΠΈΡΡ Π½Π° Π±ΠΈΠΎΠΌΠ΅Ρ
Π°Π½ΠΈΡΠ΅ΡΠΊΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π°ΡΠΎΡΠ΅ Ocular Response Analyzer, Π±Π΅ΡΠΊΠΎΠ½ΡΠ°ΠΊΡΠ½ΡΡ ΡΠΎΠ½ΠΎΠΌΠ΅ΡΡΠΈΡ ΠΏΡΠΈΠ±ΠΎΡΠΎΠΌ Canon TX-20P ΠΈ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠΎΠ½ΠΎ- ΠΌΠ΅ΡΡΠΎΠΌ Icare. ΠΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π·Π° Π΄Π΅Π½Ρ Π΄ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Π°Π½ΡΠΈΠ³Π»Π°ΡΠΊΠΎΠΌΠ½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π°, Π½Π° ΡΠ»Π΅Π΄ΡΡΡΠΈΠΉ Π΄Π΅Π½Ρ ΠΈ ΡΠ°ΠΊΠΆΠ΅ ΡΠ΅ΡΠ΅Π· 2 Π½Π΅Π΄Π΅Π»ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ. ΠΡΠΈ Π²ΡΡΠΎΠΊΠΈΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΡΡ
Π²Π½ΡΡΡΠΈΠ³Π»Π°Π·Π½ΠΎΠ³ΠΎ Π΄Π°Π²Π»Π΅Π½ΠΈΡ (ΠΠΠ) (Π΄ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Π°Π½ΡΠΈΠ³Π»Π°ΡΠΊΠΎΠΌΠ½ΠΎΠΉ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ) Π±ΡΠ»ΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΡΠΎΠ½ΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π²ΡΠ΅ΠΌΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΠΌΠΈ ΠΏΡΠΈΠ±ΠΎΡΠ°ΠΌΠΈ. Π’Π°ΠΊΠΆΠ΅ Π±ΡΠ»ΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π² ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΡ
ΠΠΠ ΠΏΡΠΈ ΡΠΎΠ½ΠΎΠΌΠ΅ΡΡΠΈΠΈ Icare Π² ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π·ΠΎΠ½Π΅ ΡΠΎΠ³ΠΎΠ²ΠΈΡΡ ΠΈ Π½Π° ΡΡΠ΅Π΄Π½Π΅ΠΉ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΠΈ Π² Π½ΠΎΡΠΎΠ²ΠΎΠΌ ΠΈ Π²ΠΈΡΠΎΡΠ½ΠΎΠΌ ΡΠ΅ΠΊΡΠΎΡΠ°Ρ
. ΠΠ° ΡΠ»Π΅Π΄ΡΡΡΠΈΠΉ Π΄Π΅Π½Ρ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½Π°Ρ ΡΠ°Π·Π½ΠΈΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΡΠΎΡ
ΡΠ°Π½ΡΠ»Π°ΡΡ, Π·Π° ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Icare. Π§Π΅ΡΠ΅Π· 2 Π½Π΅Π΄Π΅Π»ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ ΡΠΎΠ½ΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΎΠ±ΠΎΠΉ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½Π΅ ΡΠ°Π·Π»ΠΈΡΠ°Π»ΠΈΡΡ. Π ΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΠΠ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²Π°ΠΆΠ½ΡΠΌ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΏΠ»Π°Π½Π΅ ΡΠΎΠ½ΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΌ, ΠΏΠΎΡΠΊΠΎΠ»ΡΠΊΡ ΡΡΠΈΡΡΠ²Π°Π΅Ρ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ Π³Π»Π°Π·Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΡΠΈ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π³Π»Π°ΡΠΊΠΎΠΌΠΎΠΉ ΡΡΠΎΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΎΡΠ»ΠΈΡΠ°Π΅ΡΡΡ ΠΏΡΠΈ Π½Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ ΠΠΠ, ΡΡΠΎ Π²Π°ΠΆΠ½ΠΎ Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΏΡΠ°Π²ΠΈΠ»ΡΠ½ΠΎΠΉ ΡΠ°ΠΊΡΠΈΠΊΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΡΠΈ ΠΎΡΠ΅Π½ΠΊΠ΅ ΠΠΠ ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ Π΄Π°Π½Π½Π°Ρ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΡΠΎΡ
ΡΠ°Π½ΡΠ»Π°ΡΡ, ΡΡΠΎ ΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΡΡ Π½Π΅Π΄ΠΎΠΎΡΠ΅Π½ΠΊΡ ΠΎΡΡΠ°Π»ΡΠΌΠΎΡΠΎΠ½ΡΡΠ° (ΠΏΠ΅ΡΠ΅ΠΎΡΠ΅Π½ΠΊΡ ΡΡΡΠ΅ΠΊΡΠ° ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ). ΠΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΡΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π΅ΡΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°- Π½ΠΈΡ Π½Π° ΠΏΠ°ΡΠ½ΡΡ
Π½Π΅ΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π³Π»Π°Π·Π°Ρ
Transgenerational Phenomenon of Genomic Instability in Children of Irradiated Parents during ChNPP
Study of families irradiated during the accident at the Chernobyl nuclear power plant revealed significantly increased levels of aberrant genomes not only in irradiated of low doses parents (fathers-liquidators, fathers and mothers from territories contaminated with radionuclides (n = 106, p < 0.01)), but also in their children born in 1987-2004 after the accident (n = 159, p < 0.05). These children with different somatic pathologies were examined in the Children's Center of Radiation Protection of the Institute of Pediatrics and Children's Surgery of the RF Ministry of Public Health (head. - prof. Baleva L. S.). This is indicative of the transgenerational phenomenon of genomic instability. To elucidate this phenomenon, experiments were undertaken to model genomic instability by using fractionated in vitro Ξ³-irradiation (137Cs) of peripheral blood lymphocytes samples of the children and their parents at doses of 10, 20 and 30 cGy. The spectrum and frequency of chromosomes aberrations were studied in the 1st and 2nd cell generations. The children of irradiated parents (n=6). Children born from unirradiated parents (n = 3) served as a control. Parents: irradiated fathers (n = 3) and unirradiated mothers (n = 3). Single doses were 10 cGy, 20 cGy, 30 cGy. Fractional doses were 10 cGy + 10 cGy and 10 cGy + 10 cGy + 10 cGy. Blood samples were irradiated at 24 h intervals. Before culturing all blood samples were stored at 370 C. Cultivation of lymphocytes was carried out for 48 h and 72 h with the use of 5-BrdU added to differentiate between mitosis 1 and mitosis 2. Average frequency of aberrant genomes were significantly increased at all doses in the children of irradiated parents, as compared to the children born from un-irradiated parents. The magnitude of the elevation of the individual frequencies of aberrant genomes is accordance on the initial levels of the genome aberrations. This is indicative of individual radiosensitivity probably depending on genotypic peculiarities, initial state (sensitivity) of the genome, pathophysiological processes in the organism of children. Amplification of cells with single-break chromosome aberrations in the mitosis 2, as compared to mitosis 1 suggests the replication mechanism of realization of potential damage in DNA and the occurrence of genomic instability in succeeding cell generations
Adjuvant Therapy for Stages II and III Colon Cancer: Risk Stratification, Treatment Duration, and Future Directions
Background: To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions. Methods: PubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer. Summary: Locoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of therapy in stage ii disease remain controversial. Future directions should include genomic assays and improved study design to provide concrete evidence about the duration of adjuvant folfox or capox and about other types of chemotherapy and immunotherapy
Adenoid Hypertrophy Risk in Children Carriers of G-1082A Polymorphism of IL-10 Infected with Human Herpes Virus (HHV6, EBV, CMV)
Adenoid hypertrophy (AH) is considered one of the most common diseases in the ear, nose and throat (ENT) practice. The cause of adenoid hypertrophy in children is still unknown. The main aim of the current study was to investigate IL-10 (interleukin 10) gene polymorphisms and human herpesviruses 6 (HHV6), cytomegalovirus (CMV), and EpsteinβBarr virus (EBV) infections in children with AH. A total of 106 children with adenoid hypertrophy and 38 healthy children aged 2β11 years were included in this study. All children with adenoid hypertrophy were divided into three subgroups depending on the adenoid size. The viruses were determined via quantitative real-time polymerase chain reaction (PCR) using commercially available kits (QIAGEN, Germany). HHV6 was more frequently detected in patients with AH compared with CMV and EBV. Among the three subgroups of children with AH, HH6 and EBV were prevalent in the children with the largest adenoid size. The frequency of genotype GG tended to be higher in the control group of children. We found significantly higher frequencies of the G allele and GG and GA genotypes for IL-10 rs1800896 in the subgroup of children with the smallest size of adenoid compared with other subgroups. In conclusion, HHV6 and EBV infection could contribute to the adenoid size. The genotype GG for IL-10 rs1800896 could contribute to the resistance to adenoid hypertrophy and the spread of the adenoid tissue. Β© 2022 by the authors. Licensee MDPI, Basel, Switzerland
Adenoid Hypertrophy Risk in Children Carriers of G-1082A Polymorphism of <i>IL-10</i> Infected with Human Herpes Virus (HHV6, EBV, CMV)
Adenoid hypertrophy (AH) is considered one of the most common diseases in the ear, nose and throat (ENT) practice. The cause of adenoid hypertrophy in children is still unknown. The main aim of the current study was to investigate IL-10 (interleukin 10) gene polymorphisms and human herpesviruses 6 (HHV6), cytomegalovirus (CMV), and EpsteinβBarr virus (EBV) infections in children with AH. A total of 106 children with adenoid hypertrophy and 38 healthy children aged 2β11 years were included in this study. All children with adenoid hypertrophy were divided into three subgroups depending on the adenoid size. The viruses were determined via quantitative real-time polymerase chain reaction (PCR) using commercially available kits (QIAGEN, Germany). HHV6 was more frequently detected in patients with AH compared with CMV and EBV. Among the three subgroups of children with AH, HH6 and EBV were prevalent in the children with the largest adenoid size. The frequency of genotype GG tended to be higher in the control group of children. We found significantly higher frequencies of the G allele and GG and GA genotypes for IL-10 rs1800896 in the subgroup of children with the smallest size of adenoid compared with other subgroups. In conclusion, HHV6 and EBV infection could contribute to the adenoid size. The genotype GG for IL-10 rs1800896 could contribute to the resistance to adenoid hypertrophy and the spread of the adenoid tissue
MODERN APPROACHES IN THE DIAGNOSIS AND CONSERVING THERAPY OF ADENOMYOSIS
At this point in modern gynecology there are no uniform standards in the diagnosis and treatment of adenomyosis. This problem requires special attention, since there is a tendency to increase the incidence of this disease, especially in younger women. The paper presents the data in the literature about the different methods of diagnosis (hysteroscopy, ultrasound, MRI), and provides criteria for evaluation of these methods. Of greatest interest are the data of foreign authors on a new method of treatment of adenomyosis β magnetic resonance- guided focused ultrasound surgery